Tilray (TLRY.US), a pharmaceutical and cannabis company, gained roughly 20% in pre-market trading as the firm announced it has entered into an agreement with Grow Pharma - the leader in supplying unlicensed cannabis medicines in the UK. Under the agreement, Grow Pharma will distribute Tilray’s medical cannabis products across the United Kingdom. Tilray’s stock price skyrocketed in recent weeks, which might be associated with hopes that Joe Biden could potentially introduce federal marijuana legalisation.
Tilray (TLRY.US) gained in recent weeks as Biden is expected to support medical cannabis legalisation. Stock price climbed above key area at $22.45 and is expected to open almost 20% higher today. Source: xStation5
US OPEN: Market under pressure from AI
Hollywood on Edge: Another Round in the Battle for Warner Bros.
Norwegian Cruise Line surges 7% amid disclosed Elliott Management 10% stake 📈
BHP Results, the Copper Market, and the KGHM Correction. What You Need to Know